After forfeiting two board seats and undertaking a strategic review, AMAG Pharmaceuticals is saying goodbye to its CEO and two of its drugs. But with another med likely being pulled from the market, AMAG’s sudden decision to cut ties with its chief executive could be akin to shifting “deck chairs on the Titanic,” one analyst said.
AMAG CEO William Heiden has agreed to step down following a strategic review spurred by activist investor Caligan Partners that also recommended the sale or spinoff of two women’s health drugs, female libido treatment Vyleesi and painful sex med Intrarosa, the company said Thursday.
Heiden will stay on with AMAG through the successor search, which the company expects to wrap up by mid-2020, it said.
Industry Research
Artificial Intelligence in the Pharma Industry
How far has the adoption of AI technology come in Life Sciences? Share your thoughts in this brief, 8-minute survey. Let your voice be heard.
“It has been an honor and a privilege to lead the team at AMAG,” Heiden said in a release. “As we implement the strategic shift announced today, my fellow directors and I believe that this is the right time for the board to identify a new CEO for the next leg of AMAG’s journey.”
